An interventional study of Case review with on-duty plan (B0) and AI recommendation (B1) in Sepsis and Septic Shock, sponsored by Nanjing University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Nanjing University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.
Among the 89 studies in Shock, Septic with a site in China, this one is the 31st largest by planned enrollment of the 62 interventional ones that give a count, is one of 15 that started in 2026, is one of 41 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 89th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–90
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18+
Fan Zeng · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 4 · Phase 4 11
First in 2006; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 72 across the 62 interventional studies, 148 across the 26 observational. Of the 33 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 89 have an industry lead sponsor. The 10 most frequent:
Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.
Nanjing University has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
12 of the studies in Shock, Septic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT06692036Beijing Chao Yang HospitalAdaptive Blood Purification for the Treatment of Patients With Septic Shock | 2026-12-31 |
| NCT06990295First Affiliated Hospital of Wannan Medical CollegeFocused Ultrasound Spleen Stimulation and Inflammation in Septic Shock | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 89 studies in Shock, Septic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
When artificial intelligence (AI) recommends a treatment, clinicians must decide whether to follow it. This study tests whether showing the predicted consequences of a recommendation, in addition to the recommendation itself, helps clinicians accept appropriate advice and reject inappropriate advice.
We developed a clinician-anchored counterfactual model that compares the on-duty clinician's intravenous fluid and vasopressor plan with alternative plans for patients with sepsis. It predicts the patient's course under each plan and recommends a change only when the predicted benefit holds across several plausible assumptions about unrecorded factors; otherwise it states that the evidence is insufficient to recommend a change.
About 72 physicians from two hospitals, stratified by seniority, will review 30 retrospective, de-identified ICU decision points from patients with sepsis. In stage 1, each physician independently specifies fluid and vasopressor doses without any AI information. In stage 2, the same cases are reviewed under three conditions assigned by counterbalanced sequences: the case with the on-duty clinician's plan and no AI (B0); B0 plus the AI recommendation (B1); and B1 plus the predicted consequences of the on-duty and recommended plans (B2). The AI recommendation is identical in B1 and B2. Decision quality is assessed against plans made independently by expert intensivists. No patients are enrolled, and participants' decisions do not affect patient care.
Cases. Thirty decision points were selected from retrospective, de-identified ICU records before the experiment. Sampling was stratified so that the set includes AI recommendations to change treatment and to keep the current plan, both appropriate and inappropriate according to the expert reference. Each patient contributes one decision point, and none of the cases were used to develop the AI system.
Expert reference. A panel of intensivists who did not take part in AI development or in the experiment independently specify a fluid and vasopressor plan for every case, without AI output and without knowledge of study conditions. A participant's plan is scored by the number of dose levels by which it lies outside the range of expert plans (0 if within the range), summed over the two drugs. AI recommendations are classified as appropriate or inappropriate by the same rule before participant data are analyzed.
Analysis. Outcomes are analyzed with mixed-effects models with physician and case as crossed random effects. Secondary outcomes are tested in a prespecified order after the primary outcome to control the overall type I error.
Related non-interventional components. A retrospective comparison of clinicians' and the AI's plans and a prospective shadow deployment, in which the system ran on live ICU data without influencing treatment, are reported alongside this experiment but are not part of the randomized comparison.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 72 is close to the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version A): cases 1-10 under B0, cases 11-20 under B1, cases 21-30 under B2.
Other: Case review with on-duty plan (B0) · Other: AI recommendation (B1) · Other: AI recommendation with predicted consequences (B2)
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version B): cases 1-10 under B1, cases 11-20 under B2, cases 21-30 under B0.
Other: Case review with on-duty plan (B0) · Other: AI recommendation (B1) · Other: AI recommendation with predicted consequences (B2)
Stage 1: all 30 cases answered without AI information. Stage 2 (questionnaire version C): cases 1-10 under B2, cases 11-20 under B0, cases 21-30 under B1.
Other: Case review with on-duty plan (B0) · Other: AI recommendation (B1) · Other: AI recommendation with predicted consequences (B2)
Participants review the case together with the on-duty clinician's actual intravenous fluid rate and vasopressor dose and submit a final plan. No AI information is shown. This condition controls for the effect of a second review.
As B0, plus the AI output: either a recommended dose level for intravenous fluid and for vasopressor, shown with the corresponding dose range, or a statement that the evidence is insufficient to recommend a change.
As B1, with identical AI output, plus the model's predicted mean arterial pressure, lactate and urine output over the next 4 hours under the on-duty plan and under the recommended plan, shown as point estimates.
Distance of final treatment decisions from the range of expert plans, B2 versus B1
For each case, the number of dose levels by which the participant's final fluid and vasopressor plan lies outside the range of plans made independently by the expert panel (0 = within range), summed over the two drugs. Compared between B2 and B1 with a mixed-effects model with physician and case as crossed random effects, adjusted for stage-1 score, block position and sequence.
Time frame: At completion of the participant's stage-2 review (single online session, approximately 2 hours)
Discrimination between appropriate and inappropriate AI recommendations, B2 versus B1
Among cases in which the AI recommends changing treatment, acceptance is defined as a final plan equal to the AI-recommended dose level for the changed drug. The outcome is the interaction between condition (B2 vs B1) and recommendation appropriateness (classified by the expert-range rule before analysis) on acceptance, estimated with a mixed-effects probit model with physician and case as crossed random effects.
Time frame: At completion of the participant's stage-2 review (single online session, approximately 2 hours)
Plan to share: Undecided — De-identified participant-level responses (treatment decisions, confidence, response times, condition assignments and participant characteristics without identifiers) will be shared. Patient case material derived from source databases will be shared only as permitted by their data use agreements.
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Dec 2026, 0 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 0 months is below that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing University